ESMO 2018 | Promising immuno-oncology strategies for melanoma: LAG3, STING, RIG-I, TLR

Immunotherapy for melanoma has taken off, opening the door to a new era of therapy. Here, Thomas Gajewski, MD, PhD, of the University of Chicago Comprehensive Cancer Center, Chicago, IL, discusses new immuno-oncology strategies to improve therapy further, including potential targets following resistance to PD-1/PD-L1 inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.